Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Agentix Corp. (AGTX)
USD0.02
+0.00 (+0.00%)
US OTC Healthcare Biotechnology
Address
32932 Pacific Coast Highway 92629
Dana Point, CA, US
Dana Point, CA, US
CEO
Riazul Huda
Website
agentixcorp.com
IPO
2015-08-21
CIK 1603345 ISIN US00848A1034
Description
Agentix Corp., a company in the clinical development phase, specializes in the discovery and commercialization of therapeutic agents aimed at treating metabolic disorders. Its pipeline includes two primary candidates: AGTX-2004, a peripherally-acting CB1 receptor antagonist, which has exhibited effectiveness in animal studies for both obesity and type 2 diabetes mellitus; and AGTX-2003, a peripherally-acting CB1 receptor inverse agonist, also demonstrating positive results in animal models for obesity and non-alcoholic fatty liver diseases. The company was founded in 2013, initially known as FairWind Energy, Inc., before officially changing its name to Agentix Corp. in June 2019. Its operations are based in Dana Point, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.02
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
11.1K
Beta
0.71
Float Shares
31.69M
Free Float %
79.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | -44.74% | -58.00% | -50.70% | -44.00% | -47.50% | -70.00% | -97.34% | -99.88% | -99.83% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.02
Quality scores
Altman Z-Score
-2,463.52
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+59.4% ★ Q4'25: +44.4% (vs Q4'24)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q4'25: +7.7% (vs Q4'24)
-
Share dilution Biotechnology: -3.4%+2.1% ★ Q4'25: +0.0% (vs Q4'24)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.47× Q4'25: 0.00× (vs Q4'24)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-166.5K
OE per share TTM
-3.56
Owner's Yield
-19.79%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
2.9%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
5
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Grays Peak Ventures LLC | 2.19M | 57.40% | — | 2.19M | — | 2.19M | OO | United States | 2020-05-26 | ↗ |
| 2 | Scott Stevens | 2.19M | 57.40% | — | 2.19M | — | 2.19M | IN | United States | 2020-05-26 | ↗ |
| 3 | Eric Krogius | 1.00M | 16.87% | 1.00M | — | 1.00M | — | IN | United States | 2015-04-07 | ↗ |
| 4 | Bao Dong Han | 625.0K | 10.47% | 625.0K | — | 625.0K | — | IN | United States | 2015-04-16 | ↗ |
| 5 | Michael Winterhalter | 150.0K | 0.00% | 150.0K | — | 150.0K | — | IN | United States | 2020-09-22 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
3.00
Bullish
Buys
3
Sells
1
Shares acquired
2.32M
Shares disposed
—
Cash buys
2.00
Cash sales
—
Net activity
+2,324,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2020-03-29 | Winterhalter Michael | Director / Officer | P-Purchase | A | Common stock | 150,000 | 1.02 | 153.0K | 150,000 | — | ↗ |
| 2020-03-29 | Puzzo Thomas E | 10% Owner | — | D | Common stock | 0 | 0.00 | — | 333,000 | — | ↗ |
| 2020-03-29 | Grays Peak Ventures LLC | 10% Owner | P-Purchase | A | Common stock | 767,000 | 1.02 | 782.3K | 2,188,070 | — | ↗ |
| 2020-02-24 | Grays Peak Ventures LLC | 10% Owner | J-Other | A | Common stock | 1,407,000 | 20.44 | 28.76M | 1,421,070 | — | ↗ |
| 2019-11-22 | Winterhalter Michael | Director / Officer | S-Sale | D | Common stock | 10,015 | 20.44 | 204.7K | 0 | — | ↗ |
| 2019-11-04 | Winterhalter Michael | 10% Owner | S-Sale | D | common stock | 8,433 | 20.44 | 172.4K | 10,035 | — | ↗ |
| 2019-11-04 | Stevens Scott B | Director / Officer / 10% Owner | P-Purchase | A | common stock | 9,358 | 20.44 | 191.3K | 14,070 | — | ↗ |
| 2019-11-04 | Grays Peak Ventures LLC | 10% Owner | P-Purchase | A | common stock | 9,358 | 20.44 | 191.3K | 14,070 | — | ↗ |
| 2019-10-24 | Stevens Scott B | Director / Officer / 10% Owner | C-Conversion | D | $110,000 of 8% convertible promissory notes | 4,712 | 25.00 | 117.8K | 4,712 | — | ↗ |
| 2019-10-24 | Grays Peak Ventures LLC | 10% Owner | C-Conversion | D | $110,000 of 8% convertible promissory notes | 4,712 | 25.00 | 117.8K | 4,712 | — | ↗ |
| 2019-10-09 | Stevens Scott B | Director / Officer / 10% Owner | P-Purchase | A | $110,000 of 8% convertible promissory notes | 4,712 | 0.00 | — | 117,491 | — | ↗ |
| 2019-10-09 | Grays Peak Ventures LLC | 10% Owner | — | D | $110,000 of 8% convertible promissory notes | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-06-10 | Whalen Robert K | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-11-13 | Thomas Scott | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-04-19 | Winterhalter Michael | Director / Officer / 10% Owner | A-Award | A | Common Stock | 5,000 | 0.00 | — | 3,915,000 | — | ↗ |
| 2016-04-19 | Thomas Scott | Director | A-Award | A | Common Stock | 5,000 | 0.00 | — | 5,000 | — | ↗ |
| 2016-04-19 | Krogius Eric | Director | A-Award | A | Common Stock | 5,000 | 0.00 | — | 925,000 | — | ↗ |
| 2016-04-19 | Drust Robert | Director | A-Award | A | Common Stock | 5,000 | 0.00 | — | 192,500 | — | ↗ |
| 2016-03-10 | Winterhalter Michael | Director / Officer / 10% Owner | G-Gift | D | Common Stock | 20,000 | 0.00 | — | 3,960,000 | — | ↗ |
| 2016-03-10 | Krogius Eric | Director | G-Gift | D | Common Stock | 10,000 | 0.00 | — | 980,000 | — | ↗ |
| 2015-02-24 | Winterhalter Michael | Director / Officer / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 4,000,000 | — | ↗ |
| 2015-02-24 | Thomas Scott | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-02-24 | Krogius Eric | Director / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 1,000,000 | — | ↗ |
| 2015-02-24 | Han Bao Dong | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 625,000 | — | ↗ |
| 2015-02-24 | Drust Robert | Director | — | D | Common Stock | 0 | 0.00 | — | 187,500 | — | ↗ |
Executive team
Top executives
Shares Outstanding
40.07M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| David Fiene | Financial Controller | — | male |
| Martin Schroeder | Chief Scientific Officer & Member of Scientific Advisory Board | — | male |
| Riazul Huda | Chief Executive Officer, Chief Financial Officer & Director | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AGTX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
